Actelion AG, a specialist Swiss pharmaceutical company with a franchise in pulmonary arterial hypertension (PAH), reported a 10% gain in revenue for the first 2015 quarter to CHF 515 million (€502 million) and a 24% rise in operating profits to CHF 190 million.
